120 related articles for article (PubMed ID: 28007561)
21. In vitro and in vivo studies of different liposomes containing topotecan.
Hao YL; Deng YJ; Chen Y; Wang XM; Zhong HJ; Suo XB
Arch Pharm Res; 2005 May; 28(5):626-35. PubMed ID: 15974453
[TBL] [Abstract][Full Text] [Related]
22. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
[TBL] [Abstract][Full Text] [Related]
23. [Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 4. Topotecan binds preferably to the GC base pairs of DNA].
Strel'tsov SA; Mikheĭkin AL; Grokhovskiĭ SL; Oleĭnikov VA; Kudelina IA; Zhuze AL
Mol Biol (Mosk); 2002; 36(5):912-30. PubMed ID: 12391856
[TBL] [Abstract][Full Text] [Related]
24. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
Saito R; Krauze MT; Noble CO; Drummond DC; Kirpotin DB; Berger MS; Park JW; Bankiewicz KS
Neuro Oncol; 2006 Jul; 8(3):205-14. PubMed ID: 16723630
[TBL] [Abstract][Full Text] [Related]
25. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
26. Copper-topotecan complexation mediates drug accumulation into liposomes.
Taggar AS; Alnajim J; Anantha M; Thomas A; Webb M; Ramsay E; Bally MB
J Control Release; 2006 Aug; 114(1):78-88. PubMed ID: 16842880
[TBL] [Abstract][Full Text] [Related]
27. Interaction of clinically important human DNA topoisomerase I poison, topotecan, with double-stranded DNA.
Streltsov S; Oleinikov V; Ermishov M; Mochalov K; Sukhanova A; Nechipurenko Y; Grokhovsky S; Zhuze A; Pluot M; Nabiev I
Biopolymers; 2003; 72(6):442-54. PubMed ID: 14587067
[TBL] [Abstract][Full Text] [Related]
28. Determination of key parameters for a mechanism-based model to predict Doxorubicin release from actively loaded liposomes.
Csuhai E; Kangarlou S; Xiang TX; Ponta A; Bummer P; Choi D; Anderson BD
J Pharm Sci; 2015 Mar; 104(3):1087-98. PubMed ID: 25561354
[TBL] [Abstract][Full Text] [Related]
29. Sustained-release hydrogels of topotecan for retinoblastoma.
Taich P; Moretton MA; Del Sole MJ; Winter U; Bernabeu E; Croxatto JO; Oppezzo J; Williams G; Chantada GL; Chiappetta DA; Schaiquevich P
Colloids Surf B Biointerfaces; 2016 Oct; 146():624-31. PubMed ID: 27429296
[TBL] [Abstract][Full Text] [Related]
30. Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator?
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
Int J Pharm; 2010 Oct; 399(1-2):31-6. PubMed ID: 20678563
[TBL] [Abstract][Full Text] [Related]
31. Structural spectroscopy and dynamics of inter- and intramolecular H-bonding interactions of topotecan, a potent anticancer drug, in organic solvents and in aqueous solution.
di Nunzio MR; Wang Y; Douhal A
J Phys Chem B; 2012 Jun; 116(25):7522-30. PubMed ID: 22662747
[TBL] [Abstract][Full Text] [Related]
32. Optimization of liposomal topotecan for use in treating neuroblastoma.
Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB
Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814
[TBL] [Abstract][Full Text] [Related]
33. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
34. Topotecan hydrochloride liposomes incorporated into thermosensitive hydrogel for sustained and efficient in situ therapy of H22 tumor in Kunming mice.
Xing J; Qi X; Jiang Y; Zhu X; Zhang Z; Qin X; Wu Z
Pharm Dev Technol; 2015 Nov; 20(7):812-819. PubMed ID: 24909735
[TBL] [Abstract][Full Text] [Related]
35. A Critical Scrutiny on Liposomal Nanoparticles Drug Carriers as Modelled by Topotecan Encapsulation and Release in Treating Cancer.
Mills H; Acquah R; Tang N; Cheung L; Klenk S; Glassen R; Pirson M; Albert A; Hoang DT; Van TN
Evid Based Complement Alternat Med; 2022; 2022():7702512. PubMed ID: 35983007
[TBL] [Abstract][Full Text] [Related]
36. [Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. III. Binding at the minor groove].
Strel'tsov SA; Mikheĭkin AL; Grokhovskiĭ SL; Oleĭnikov VA; Zhuze AL
Mol Biol (Mosk); 2002; 36(3):511-24. PubMed ID: 12068638
[TBL] [Abstract][Full Text] [Related]
37. Determination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis method.
Modi S; Anderson BD
Mol Pharm; 2013 Aug; 10(8):3076-89. PubMed ID: 23758289
[TBL] [Abstract][Full Text] [Related]
38. pH-sensitive liposomes bearing a chemotherapeutic agent and a natural apoptosis modulator for effective intracellular delivery to the solid tumor.
Saraf S; Jain SK
Drug Deliv Transl Res; 2023 Dec; 13(12):2961-2981. PubMed ID: 37306925
[TBL] [Abstract][Full Text] [Related]
39. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
40. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
